<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>24(4)</volume><submitter>Xu M</submitter><pubmed_abstract>Therapeutic antibodies-F(ab')&lt;sub>2&lt;/sub> obtained from hyperimmune equine plasma could treat emerging infectious diseases rapidly because of their high neutralization activity and high output. However, the small-sized F(ab')&lt;sub>2&lt;/sub> is rapidly eliminated by blood circulation. This study explored PEGylation strategies to maximize the half-life of equine anti-SARS-CoV-2 specific F(ab')&lt;sub>2&lt;/sub>. Equine anti-SARS-CoV-2 specific F(ab')&lt;sub>2&lt;/sub> were combined with 10 KDa MAL-PEG-MAL in optimum conditions. Specifically, there were two strategies: Fab-PEG and Fab-PEG-Fab, F(ab')&lt;sub>2&lt;/sub> bind to a PEG or two PEG, respectively. A single ion exchange chromatography step accomplished the purification of the products. Finally, the affinity and neutralizing activity was evaluated by ELIS</pubmed_abstract><journal>International journal of molecular sciences</journal><pagination>3387</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9963672</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>PEGylation Prolongs the Half-Life of Equine Anti-SARS-CoV-2 Specific F(ab')&lt;sub>2&lt;/sub>.</pubmed_title><pmcid>PMC9963672</pmcid><pubmed_authors>Mo R</pubmed_authors><pubmed_authors>Feng N</pubmed_authors><pubmed_authors>Xia X</pubmed_authors><pubmed_authors>Xu M</pubmed_authors><pubmed_authors>Wang T</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Yang S</pubmed_authors><pubmed_authors>Bi J</pubmed_authors><pubmed_authors>Zhao Y</pubmed_authors><pubmed_authors>Liang B</pubmed_authors><pubmed_authors>Yan F</pubmed_authors></additional><is_claimable>false</is_claimable><name>PEGylation Prolongs the Half-Life of Equine Anti-SARS-CoV-2 Specific F(ab')&lt;sub>2&lt;/sub>.</name><description>Therapeutic antibodies-F(ab')&lt;sub>2&lt;/sub> obtained from hyperimmune equine plasma could treat emerging infectious diseases rapidly because of their high neutralization activity and high output. However, the small-sized F(ab')&lt;sub>2&lt;/sub> is rapidly eliminated by blood circulation. This study explored PEGylation strategies to maximize the half-life of equine anti-SARS-CoV-2 specific F(ab')&lt;sub>2&lt;/sub>. Equine anti-SARS-CoV-2 specific F(ab')&lt;sub>2&lt;/sub> were combined with 10 KDa MAL-PEG-MAL in optimum conditions. Specifically, there were two strategies: Fab-PEG and Fab-PEG-Fab, F(ab')&lt;sub>2&lt;/sub> bind to a PEG or two PEG, respectively. A single ion exchange chromatography step accomplished the purification of the products. Finally, the affinity and neutralizing activity was evaluated by ELIS</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-21T14:37:00.016Z</modification><creation>2025-04-21T14:37:00.016Z</creation></dates><accession>S-EPMC9963672</accession><cross_references><pubmed>36834803</pubmed><doi>10.3390/ijms24043387</doi></cross_references></HashMap>